Division of UnitedHealth Group Co.
Latest From Catamaran Corp.
PBMs have become a central focus of the drug pricing debate, thanks in large part to the biopharma industry’s efforts to shine a spotlight on the role of rebates and middlemen in consumer costs. They were also a surprising focus on a hearing about health industry consolidation.
The year 2015 could give 2014 a run for the money in terms of biopharma M&A deal value. From January through August, 18 deals were signed with an upfront value of more than $1bn, representing a total upfront value of $133bn.
There are lots of moving parts to reconcile before the PBM situation is settled for the combined Anthem-Cigna entity, and a decision is not expected until after the expected closing of the acquisition in the second half of 2016.
- Therapeutic Areas
- SXC Health Solutions
- North America
- Parent & Subsidiaries
- UnitedHealth Group Co.
- Senior Management
Mark Thierer, Chmn. & CEO
Mike Shapiro, SVP & CFO
Michael Edwards, SVP, Sales & Acct. Mgt.
Sumit Dutta, MD, CMO
- Contact Info
Phone: (800) 282-3232
1600 McConnor Pkwy.
Schaumburg, IL 60173-6801
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.